Skip to main content
Home > BioCentury on BioBusiness > Finance/Investment

Chronological Index of : Finance

 Current Issue
  • Figure: Clinical rationing

    Cash cravings Clinical rationing The total raised by private and public European biotechs increased by 57% to $9 billion in 2014 from $5.8 billion in 2013. Funding for companies in the clinic or with a marketed …

    Published on 5/25/2015
  • Figure: Europe's total demand

    Cash cravings Europe's total demand BioCentury projects that private and public European biotech companies with compounds in the clinic and beyond will need a record $6 billion to keep their programs on track …

    Published on 5/25/2015
  • Figure: Private demand

    Cash cravings Private demand The aggregate three-year demand for private European biotechs in the clinic and beyond is estimated to be $5 billion, slightly below the $5.1 billion in last year’s survey. On a euro …

    Published on 5/25/2015
  • Figure: Public demand

    Cash cravings Public demand The aggregate three-year capital demand for unprofitable European public biotechs in the clinic and beyond reached $946.6 million, up 62% from $585.8 million in the 2014 survey. …

    Published on 5/25/2015
  • Table: New funds

    Cash cravings New funds Since the start of 2014, at least 30 life science funds with a European presence are raising or have raised a total of more than $9 billion. (A) Invests in private and public companies; (B)…

    Published on 5/25/2015
  • Figure: Money Raised in 2015

    Dollars for vectors Money Raised in 2015 Last week, the biotech industry raised $597 million, bringing to $47.5 billion the total raised year-to-date. In 2014, a total of $54.6 billion was raised, including $21.5 …

    Published on 5/25/2015
  • Innovation underfed

    Europe's Iceberg 2015: Finance at root of translational gap in innovation

    Innovation is a predictor of access to capital and partnering success, but investors say lack of the former is holding back Europe's innovators.

    Published on 5/25/2015
  • Figure: Capital rationing

    Innovation underfed Capital rationing In 2014, the average venture raised per private European company increased by 21% to $17.5 million from $14.4 million in 2013. The boost was helped by an unspecified $85 …

    Published on 5/25/2015
  • Figure: EU vs. U.S. private funds raised

    Innovation underfed EU vs. U.S. private funds raised Money raised by private U.S. companies increased by 61% to $6.5 billion in 2014 from 2013, while European private companies saw a 11% increase in funding to $1.…

    Published on 5/25/2015
  • Figure: EU vs. U.S. public funds raised

    Innovation underfed EU vs. U.S. public funds raised The top figure shows that the amount raised via equity financings by public European biotechs increased by 2.6x to $4.7 billion from 2013 vs. a 1.5x increase in …

    Published on 5/25/2015
  • Figure: Global competition for capital

    Innovation underfed Global competition for capital Total funding for both Europe and the U.S. increased from 2013 to 2014. The money raised by European companies increased by 57% to $9 billion, while U.S. …

    Published on 5/25/2015
  • Figure: Innovation pays

    Innovation underfed Innovation pays Of 225 private Phase II companies included in BioCentury's annual European Iceberg survey from 2011 to 2013, a subset of 133 deemed innovators raised significantly more cash, …

    Published on 5/25/2015
  • Cash cravings

    Results of BioCentury's 13th survey of funding needs for European biotechs

    BioCentury's 13th annual European Iceberg survey foresees record financing demand, lifted by higher cash burn and more public biotechs.

    Published on 5/25/2015
  • Dollars for vectors

    Why crossovers flooded series D for gene therapy play RegenxBio

    Finance Ebb & Flow Dollars for vectors Figure: Money Raised in 2015 RegenxBio Inc. has tapped investors for more than $100 million this year, including last week's $70.5 million series D round, but may return …

    Published on 5/25/2015
  • Sour cocktail hour

    Why investors hosed HCV play Achillion after J&J deal

    Finance Sour cocktail hour A blend of lofty investor expectations and dilution are the likely reasons why Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) lost value after partnering its HCV assets with Johnson & …

    Published on 5/25/2015
  • London calling

    Why U.S. biotech Verseon decided to list on London's AIM

    Finance London calling European companies have been flocking to NASDAQ to raise cash from U.S. investors. But California's Verseon Corp. (LSE:VSN) decided to swim against the tide all the way to London to ensure it …

    Published on 5/25/2015
  • Figure: Money Raised in 2015

    Gassing up for royalties Money Raised in 2015 Last week, the biotech industry raised $918 million, bringing to $46.8 billion the total raised year-to-date. In 2014, a total of $54.6 billion was raised, including $…

    Published on 5/18/2015
  • New (Bio)ventures at MPM

    How MPM wants to deploy its new $400 million fund

    Finance New (Bio)ventures at MPM With its new $400 million fund, MPM is in build mode — launching newcos either as option deals for its two strategic LPs or for the long haul with the firm's increased number of …

    Published on 5/18/2015
  • Gassing up for royalties

    How Royalty Pharma will spend its newly raised $1 billion

    Finance Ebb & Flow Gassing up for royalties Figure: Money Raised in 2015 Royalty Pharma has refilled its tank with a $1 billion equity raise and plans to use a portion of the money to ramp up its search for …

    Published on 5/18/2015
  • BeiGene going global

    Why cancer play BeiGene raised second-largest ever Chinese venture round

    Finance BeiGene going global BeiGene Co. Ltd.'s existing and new investors have ponied up the second largest ever venture round for a Chinese biotech, as the company looks to globalize its clinical development and …

    Published on 5/18/2015
  • Planting Fidelity's seeds

    Why Fidelity decided to help create neurodegenerative play Denali

    Newco Denali could serve as a repository for discoveries from academic seed investments from the Fidelity Biosciences Research Initiative.

    Published on 5/18/2015
  • Figure: Money Raised in 2015

    Debuting Biocartis Money Raised in 2015 Last week, the biotech industry raised $2.9 billion, bringing to $45.7 billion the total raised year-to-date. In 2014, a total of $54.6 billion was raised, including $21.5 …

    Published on 5/11/2015
  • Table: Earnings on deck

    Debuting Biocartis Earnings on deck At least 13 biotechs and pharmas are expected to report earnings this week. (A) EPS for fiscal year ended March 31, 2014; (B) EPS for fiscal 4Q ended March 31, 2014 Company …

    Published on 5/11/2015
  • Table: Euronext debuts

    Debuting Biocartis Euronext debuts Half of the 20 IPOs on Euronext since 2012 gained in their first day of trading. (A) Formerly Cardio3 BioSciences S.A.; Source: BCIQ: BioCentury Online Intelligence Company …

    Published on 5/11/2015
  • White space with graybeards

    How Flagship is exploring white space with established partners

    Flagship Ventures has decided the best way to identify and explore white space is by tapping large partners.

    Published on 5/11/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993